| Assessment Status |
Rapid Review Complete |
| HTA ID |
26014 |
| Drug |
Durvalumab |
| Brand |
Imfinzi® |
| Indication |
Durvalumab (Imfinzi®) is indicated in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adults with resectable gastric or gastro oesophageal junction adenocarcinoma. |
| Rapid review commissioned |
20/03/2026 |
| Rapid review completed |
29/04/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab, for this indication, compared with the current standard of care. |
| Full HTA commissioned by the HSE |
30/04/2026 |
